| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | -25441.33% | -24457.53% | -23044.07% | -8118.63% | 21.17% |
| EBITDA Margin | — | — | -25260.00% | -24228.77% | -22652.54% | -7932.35% | 22.47% |
| Net Margin | — | — | -26082.67% | -24942.47% | -23528.81% | -8111.76% | 21.39% |
| Current Ratio | 54.67 | 10.49 | 0.94 | 1.90 | 15.05 | 9.51 | 7.10 |
| Quick Ratio | 54.67 | 10.49 | 0.94 | 1.90 | 15.05 | 9.51 | 7.10 |
| Debt / Equity | — | — | — | — | — | — | — |
| ROE | -38.97% | -46.04% | -9684.16% | -631.78% | -69.38% | -80.82% | 15.72% |
| ROA | -38.07% | -41.66% | -438.22% | -304.84% | -64.93% | -71.41% | 13.56% |
| Asset Turnover | — | 0.00 | 0.02 | 0.01 | 0.00 | 0.01 | 0.63 |
| Book Value / Share | 2.69 | 11.64 | 0.15 | 0.35 | 4.66 | 10.03 | 19.37 |
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines for chronic and life-threatening conditions. It employs its proprietary Silence and Replace platform, which combines DNA-directed RNA interference with gene therapy to enable sustained silencing of disease-causing genes and delivery of replacement genes via a single administration. The lead product candidate, BB-301, is an AAV-based gene therapy targeting dysphagia associated with oculopharyngeal muscular dystrophy, a genetic disorder affecting swallowing function. This platform addresses unmet needs in gene-associated diseases lacking effective treatments. Benitec Biopharma Inc. operates within the biotechnology sector of healthcare, advancing therapeutics through clinical trials and regulatory interactions, including Fast Track and Orphan Drug designations. Headquartered in Hayward, California, the company contributes to innovative solutions in genetic medicine by leveraging RNAi and gene therapy technologies.